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ABSTRACT                        Morphine is the most widely used compound among narcotic analgesics and 
remains the gold standard when the effects of other analgetic drugs are compared. The most 
characteristic effect of morphine is the modulation of pain perception resulting in an increase 
in the threshold of noxious stimuli. Antinociception induced by morphine is mediated via opioid 
receptors, namely the µ-type opioid receptor. Apart from the µ-opioid receptor, two other classi-
cal opioid receptors κ- and δ- and one non-classical opioid receptor, the nociceptin receptor was 
discovered and cloned so far. At the same time endogenous opioids were also discovered, such as 
enkephalins, endorphins, and dynorphins. The opioid receptors together with the endogenous 
opioids form the so called endogenous opioid system, which is highly distributed throughout 
the body and apart from analgesia it has several other important physiological functions. In 
this article we will review the historical milestones of opioid research − in detail with morphine. 
The review will also cover the upmost knowledge in the molecular structure and physiological 
effects of opioid receptors and endogenous opioids and we will discuss opioid receptor model-
ling − a rapidly evolving field in opioid receptor research.
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The narcotic analgesics, of which morphine is the prototype, 
produce a large variety of pharmacological responses by 
interacting with the opioid receptors in the nervous system. 
Morphine is one of the agonist ligands for multiple opioid 
receptors (µ, δ and κ) and therefore the majority of its ef-
fects is attributed to specific drug-receptor interactions. This 
idea is based on morphine actions that can be competitively 
blocked by opiate antagonists, such as naloxone, naltrexone 
or diprenorphine. Morphine is a natural compound, the prin-
cipal alkaloid in opium and becoming the prototype opiate 
analgesic and narcotic.
Analgesic and other important effects of morphine-type 
drugs, including natural, semisynthetic and synthetic deriva-
tives have been well established (Martin 1983; Yaksh and 
Noueihed 1985; Wood and Iyengar 1988; Jaffe and Martin 
1990; Pasternak 1993; Spetea 2013). The question of mor-
phine tolerance and dependence is not included in this paper, 
thus the reader can refer to several reviews (Cox 1991; Trujillo 
and Akil 1991; Di Chiara and North 1992; Meunier 1992).
Historical background
Many of pharmacological actions of morphine, including 
analgesia, euphoria and constipation had clearly been known 
long before morphine itself was isolated. In several early 
civilizations, such as Sumeria, Egypt, ancient Greece and 
the Roman empire, extracts of the poppy plant (Papaver 
somniferum) were thoroughly used as medicine. Theriaca, 
opium, laudanum pulvis Doveri and paregoric, each contains 
morphine in substantial amounts, and they have been used for 
centuries in western medicine. Several similar extracts are 
still in use, e.g., to treat some kind of diarrhoeas. Morphine, 
as the major active ingredient of opium, was isolated in 1805 
by the German pharmacist Wilhelm Sertürner (1805) and 
subsequently named after Morpheus the god of dreams in 
Greek-Roman mythology. Morphine was the first alkaloid to 
be discovered, and its isolation therefore was a breakthrough 
in organic chemistry. Soon thereafter morphine became one 
of the most popular drugs for therapy. Besides their medicinal 
use, morphine-containing drugs and later pure morphine, 
served as recreational agents and this contributed to the illicit 
applications. Thus opium was accepted in classical Islamic 
countries such as Arabia, Turkey and Iran, where opium 
eating and smoking replaced the consumption of alcoholic 
drinks. Opium was also consumed as a favourite substance 
of pleasure in India and China. Unfortunately, morphine and 
18
Benyhe et al.
heroin are still among the most dangerous drugs all over the 
world, and the abuse of opiates represents serious problems 
in societies. A schematic timeline illustrating the milestones 
in morphine and opioid receptor research is shown in Figure 
1.
Chemistry
Morphine is a member of the morphinan-framed alkaloids 
(other name of the ring system is: perhydrophenantrene), 
including codeine, thebaine, neopinone and morphine itself. 
They are predominantly found in the plant genus of Papaver. 
The structure of morphine (Gulland and Robinson 1925) 
consists of five condensed rings: phenolic A, cyclohexane 
B, cyclohexenol C, N-methyl-piperidine D and a partially 
saturated furan ring E (Fig. 2).
The stereochemical structure has been confirmed by 
X-ray diffraction analysis (Mackay and Crowfoot-Hodgkin 
1955; Fridrichsons et al. 1968). This frame is rather struc-
turally rigid, but some functional groups of morphine, such 
Figure 1. Milestones in morphine and opioid research.
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as the C3 phenolic and C6 secondary alcoholic, allow the 
compound to be chemically reactive. Due to the piperidine 
ring, morphine is a weak base: the collective name ‘alkaloid’, 
that is plant-derived natural compounds having an N-atom 
in their structure reflects this property. Natural morphine is 
optically active being levorotatory molecule, but its synthetic 
counterpart (+)morphine has been shown to display entirely 
different biological effects (Jacquet et al. 1977). The mor-
phine molecule has five chiral centers on the carbon atoms 
of 5, 6, 9, 13, 14. The absolute configuration of asymmetric 
carbon atoms in the natural morphine is: 5R6S9R13Sl4R. 
Multiple pharmacological effects of morphine are ascribed 
to this stereochemical structure and only limited action of (+)
morphine has been recorded (Adams et al. 1991).
Receptors for opioids
Receptor theory
Bioactive compounds (alkaloids, drugs, toxins, etc.) produce 
a wide range of biological responses in the body. At the begin-
ning of the 20. century Paul Ehrlich postulated that „Corpora 
non agunt nisi fixata” (compounds only act when they are 
bound). Central nervous system (CNS) mechanisms of vari-
ous drugs have not been fully understood. It was proposed by 
Ehrlich, Dale and others that therapeutic and toxic effects of 
drugs result from their interactions with specific molecules 
in the body. These molecules are called ’receptors’: recep-
tors are usually proteinaceus macromolecules consisting of 
single chain or multiple glycoproteins. Interaction of a small 
(first messenger) molecule with the receptor is followed by 
receptor activation that initiates further, mainly intracellular, 
events in the signal transduction cascade. Receptor activation 
often modulates synaptic transmission in nervous tissues. In 
fact, neurotransmitters are typical compounds that interact 
with pre- or postsynaptic receptor molecules. Response to a 
messenger molecule depends on the binding capacity of the 
receptors. Localisation of the receptors may be in the cell 
surface, in the cytosol or in the nucleus. We can refer to the 
signaling ’messenger’ molecule (e.g. hormone or neurotrans-
mitter) as the ligand, which interact with specific recognition 
sites, named ’binding pocket’ on the receptor. Ligand binding 
to the receptors is followed by conformational changes and 
a sequence of intracellular reactions (transmembrane signal-
ing). They generate, amplify, coordinate, and terminate post 
receptor signaling by chemical secondary messengers located 
in the cytoplasm, leading to a change in cellular function. Be-
ing aware of these facts, receptors have become the central 
focus investigating drug effects.
In a pharmacological point of view ligands may be ago-
nists or antagonists. An agonist can bind to the receptor and 
activates it producing cellular and other responses. Antago-
nists are capable of blocking the agonist binding, thus the 
pharmacological effect of the primary drug is inhibited. Pure 
antagonists alone do not mediate pharmacological effects un-
less they are able to inhibit the receptor stimulating effects 
of endogenous agonist ligands. The typical mechanism by 
which antagonists work is competitive binding and inhibition. 
Partial agonists can produce less biological responses than 
full agonists do. Inverse agonists are compounds that interact 
with the same receptor as an agonist but induce biological 
responses opposite to that of antagonists.
The interaction between ligand and receptors can be quan-
tified in radioligand binding assays or radioreceptor binding 
assays. In such studies a radiolabelled chemical named ‘ra-
dioligand’ (L*), usually a small molecule will interact with 
the receptor protein macromolecule:
[L*] + [R] ↔ [RL*] 
where [R] is the receptor concentration, [RL*] is the concen-
tration of the receptor ligand complex, or the ‘bound ligand’. 
In practice, the quantity of the bound ligand is measured by 
filtration methods. Ideally, candidate ligands for radiolabel-
ing should have the following desirable properties: (i) high 
affinity to favour specific over non-specific binding, (ii) low 
non-specific binding, (iii) high specific (molar) radioactiv-
ity to detect low receptor densities, (iv) receptor specificity. 
Further properties of specific binding are reversibility, satu-
rability, stereospecificity and competitiveness. Radioligand 
binding assays evolved rapidly during the characterization 
of opioid receptor.
Figure 2. Structure of morphine. A: phenolic ring, B: cyclohexane 




Opioid receptors: discovery and heterogeneity
Among others the opioid system is involved in regulating 
pain, some vegetative functions, reward mechanisms and 
drug addiction. Natural and synthetic opioids exert their phar-
macological actions through three opioid receptors. As the 
opioid recetor concentration is very low in different tissues, 
its discovery had been challenged until highly specific [3H]
labelled radioligands with high molar radioactivity become 
available. By the use of brain membrane preparations and 
[3H]dihydromorphine (agonist) or [3H]naloxone (antagonist) 
radioligands with high molar activity led to the discovery of 
the brain’s opioid receptors (Terenius 1973; Pert and Snyder 
1973; Simon et al. 1973). The key step in identifying opioid 
receptors was to establish an in vitro method to determine 
non-specific binding. Non-specific binding can be measured 
in the simultaneous presence of the labelled ligand (in nano-
molar concentration) and an excess of unlabelled ligand (in 
micromolar concentration). Latter may be either chemically 
identical with the radiolabelled ligand (homologous competi-
tion) or represents a chemically different compound that act 
on the same receptor. Radioligand binding studies are still 
fundamental methods investigating ligand-receptor interac-
tions. Early studies defined a saturable binding site, which 
bound opioids with nanomolar affinity. The sites were the 
first in which the binding of agonists and antagonists could 
be distinguished by sodium ions (Pert et al. 1973), divalent 
cations (Pasternak et al. 1975), and protein modifying re-
agents (Wilson et al. 1975). Evidence for heterogenous opioid 
receptors or receptor multiplicity came from the demonstra-
tion of different pharmacological profiles observed on chronic 
spinal dogs by the use of three prototype opioid agonists: 
morphine, ketocyclazocine and SKF-10,047 (Martin et al. 
1976). Three types of opioid receptors were proposed named 
after the drugs used in the studies: µ, κ, and σ. The presence 
of distinct δ-opioid receptors was suggested to explain the 
naloxone-sensitive inhibitions of Met- and Leu-enkephalins 
on the electrically stimulated mouse vas deferens preparations 
(Lord et al. 1977). The σ-receptor is targeted by phencyclidine 
(PCP) and its analogues (Monassier and Bousquet 2002), and 
it is no longer regarded as an opioid receptor. To date there 
are three well-defined or ‘classical’ types of opioid receptor, 
MOP, DOP and KOP, but other designations are also accepted 
(see Table 1). 
Opioid receptors are widely distributed throughout the 
brain and periphery. In the perifery they are found in certain 
smooth muscles: ileum, vas deferens; myenteric plexus of the 
gut, and in adrenal medulla, heart, retina, placenta (Cox 1988). 
Opioid receptor activation by ligands results in a multitude of 
effects. Generally, MOP or DOP receptors selective agonists 
are analgesic and rewarding, KOP receptor selective agonists 
are dysphoric (Waldhoer et al. 2004). DOP receptors have a 
role in analgesia (Stewart and Hammon 1993), motor integra-
tion, gastrointestinal motility, respiration, olfaction, cognitive 
function and mood driven behaviour. Medullary DOP recep-
tors are important in cardiovascular regulation (Arndt 1987). 
KOP receptors have a role in nociception, diuresis, feeding 
and neuroendocrine secretions (Hansen and Morgan 1984), 
control of immune function, thermoregulation (Handler et al. 
1992) and modulation of cardiorespiratory function (Hassen 
et al. 1984). KOP receptor agonists can produce dysphoria 
in humans (Pfeiffer et al. 1986). MOP receptor agonists are 
potent antinociceptive drugs (Paul et al. 1989). MOP recep-
tors have a role in respiration, cardiovascular functions, in-
testinal transit (Fox-Threlkeld et al. 1994), feeding, learning 
and memory, locomotor activity, thermoregulation (Handler 
et al. 1994), hormone secretion, and immune functions, all 
of which, except hormone secretion, are depressed by MOP 
receptor stimulation. The respiratory depressant effects of 
MOP receptor agonists result from a decrease in sensitivity of 
respiratory centers to hypercapnia (Butelman et al. 1993).
Opioid receptors: molecular structure
Opioid receptors belong to the superfamily of the G-protein 
coupled receptors (GPCRs) constituting one of the larg-
est family of the receptors (Fredriksson et al. 2003). The 
GPCRs are located in the cell membrane and most of them 
are activated by molecules outside the cell to trigger signal 
transduction pathways inside the cell (Rosenbaum et al. 2009; 
Kobilka 2007). However, there are a large number of these 
receptors lacking known ligands denoted as orphan receptors. 
Some of them supposed not to need a ligand for activation 
but they are self-activated by heterodimerization (Levoye et 
al. 2006). GPCRs are found only in eukaryotes, including 
animals, choanoflagellates and yeast. The importance of the 
GPCRs in human may be highlighted by their abundance. 
More than 800 GPCR coding genes have been identified 
Table 1. Heterogeneity of the opioid receptors








Typical agonist Selective               
antagonist
MOP, µ or mu (MOR) OP3 heptahelical 400 aa endomorphins morphine cyprodime
DOP, δ or delta (DOR) OP1 heptahelical 372 aa enkephalins Leu-enkephalin naltrindole
KOP, κ or kappa (KOR) OP2 heptahelical 380 aa dynorphin U-69,593 norbinaltor-
phimine
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so far in the human genome which is ca. 4% of the entire 
protein-coding genome. From the medicinal point of view, 
40-50% of the existing drugs target some of the GPCRs. Due 
to their involvement in the pain pathways and the drug abuse, 
opioid receptors have a long history of medical treatments. 
The GPCR family can be divided to five main classes with no 
noticeable sequence homology between the classes. Opioid 
receptors belong to the class A GPCRs (the rhodopsin sub-
family), which comprise ca. 85% of the whole family. Despite 
the high sequence diversity within the GPCRs, their modular 
structure is highly conserved (Fig. 3).
The N- and C-terminal chains show the highest diversity 
within GPCRs. Also, the intra- and extracellular loops, ILs 
and ELs, respectively, are highly diverse. In contrast, the 
seven transmembrane helix region and the eighth shorter helix 
at the intracellular side of the membrane contain numerous 
conserved structural elements maintaining uniform signal 
transduction machinery. There are conserved single residues 
in the helices, among them the most conserved ones serve 
the starting points in the Ballesteros-Weinstein nomenclature 
for GPCR residue numbering being given a serial number 
50 in each helix (Ballesteros and Weinstein 1995). The three 
conserved sequence motifs, (D/E)RY, NPxxY and CWxP, 
serve as molecular switches during the receptor activation, 
namely the ionic lock switch (together with E6.30), Tyr toggle 
switch and transmission switch (or rotamer toggle switch) 
switch, respectively (Trzaskowski et al. 2012). Also, there is a 
conserved hydrogen bonding network connecting the helices 
which is supposed to change by protonation of D2.50 and 
(D/E)3.49 leading to activation (Ratnala et al. 2007; Hofmann 
et al. 2009; Dror et al. 2011a). The protonation of (D/E) 3.49 
both triggers the ionic lock and affects the interaction of the 
receptor with the membrane potential (Zhang et al. 2013). 
The protonation state of D2.50 influences the helix-helix 
interactions and has interplay with the allosteric sodium ef-
fect on agonist binding as shown both experimentally and 
theoretically (Selent et al. 2010; Fenalti et al. 2014; Shang 
et al. 2014). The glycosylation in the N-terminal tail and 
the palmitoylation at helix 8 as well as the existence of the 
cistein bridge between C3.25 and EL2 are mostly conserved 
structural elements, however with greater variation and in 
some GPCRs they are missing. Cholesterol and palmitoyla-
tion may play a role in the interactions with lipid rafts and/
or in receptor oligomerization (Chini and Parenti 2009). The 
same features can be seen in Figure 4 on a 3D model of hu-
man MOP receptor by the same color coding except that only 
protonable carboxyl oxygens are shown in red.
Two independent groups, Kieffer and co.workers (1992) 
Figure 3. Highly conserved structural features in the GPCR superfamily.
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and Evans (1992), cloned the first (mouse DOP) opioid recep-
tor using similar methods. The cloned receptor consists of 372 
amino acids. Hydropathy analysis suggests the presence of 
seven transmembrane (TM) domains within the amino acid 
sequence. Opioid receptors consist of a single polypeptide 
chain. Sequential organisation of the domains in the receptor 
protein is as follows: extracellular N-terminus, seven hydro-
phobic TM segments interconnected with 3-3 intracellular 
and extracellular loops ended with a cytoplasmic C-terminal 
tail (serpentine model). The N-terminus contains N-linked 
glycosylation sites, while multiple phosphorylation sites may 
exist in the cytoplasmic loops and C-terminal.
The rat (Fukuda et al. 1993), human (Knapp et al. 1994) 
and amphibian (Rana pipiens) (Stevens 2007) δ-receptor has 
also been cloned. Although only one DOP receptor gene has 
been cloned, on the basis of in vitro and in vivo pharmacologi-
cal characteristics a variety of DOP receptor subtypes have 








 -receptor (Jiang et al. 
1991; Portoghese et al. 1922; Vanderah 1994). 
Chen isolated the first MOP receptor cDNA clone (Chen 
et al. 1993). The rat MOP receptor consists of 398 amino ac-
ids, while the human one contains 400 amino acids (Raynor 
et al. 1995). Five potential N-linked glycosylation sites are 
present in the N-terminal. To date, MOP receptor genes have 
also been cloned from mouse (Min et al. 1994) human (Wang 
et al. 1994; Raynor et al. 1995), rhesus (Macaca mulatta) and 
crab-eating monkey (Macaca fascicularis) (Miller GM and 
Madras: direct GenBank deposit), pig (Sus scrofa) (Pampusch 
et al. 1998), cow (Bos taurus) (Onoprishvili et al. 1999) 
guinea pig (Cavia porcellus) (Smith et al.: direct GenBank 
deposit), white suckerfish (Catostomus commersoni) (Darli-
son et al. 1997), zebrafish (Danio rerio) (Barrallo 2000), and 
frog (Rana pipiens) (Stevens 2007). Weakly homologous 
sequences are also present in the genomes of Caenorhabditis 
elegans and Drosophila melanogaster. A variety of alternative 
mRNA splice variants have also been cloned and/or sug-
gested for the MOP receptor gene (Pasternak 2001a, 2001b) 
and some of the resulting proteins differ in their trafficking 
properties, although their pharmacology does not appear to 
differ in ligand binding assays (Koch et al. 2001). Thus, it is 
unlikely that these splice variants explain the observation of 





subdivision was proposed based on that [3H]-labelled, MOP, 
DOP and KOP selective ligands displayed biphasic binding 
characteristics (Wolozin and Pasternak 1981; Krizsán et al. 
1991). Each radioligand appeared to bind to the same very 
high affinity site (µ
1
) as well as to the appropriate high affinity 
site (µ, δ, κ) depending on the radioligand used. Naloxazone 
and naloxonazine were reported to abolish the binding of each 
radioligand to the µ
1




 receptors are 
involved in producing analgesia, euphoria is produced mainly 
through µ
1
, and respiratory depression through µ
2
 receptors. 
The cloning of the mouse KOP receptor occurred dur-
ing efforts to obtain mouse somatostatin receptor subtypes 
(Yasuda et al. 1993). The mouse KOP receptor consists 
of 380 amino acids. The KOP receptor has two N-linked 
glycosylation sites in the N-terminal. A number of KOP 
receptor subtypes have been described (for review see: Wol-
lemann et al. 1993); κ
1
 sites bind to dynorphin 1-17 but not 
to [d-Ala2,d-Leu5]-enkephalin (DADLE; representing the 
cloned KOP receptors profile), κ
2
 sites bind the heptapeptide 
Met-enkephalin-Arg-Phe (MERF) and DADLE (Benyhe et al. 
1997), and the so-called κ
3
 site is sensitive to naloxone ben-
zoylhydrazone (Akil and Watson 1994). MOP, DOP and KOP 
receptor subtypes may result from different posttranslational 
modifications of the gene product (glycosylation, palmytoyla-
tion, phosphorylation, etc), or from receptor oligomerization 
(Cvejic and Devi 1997).
The cloning of opioid receptors in the beginnings of the 
90s was soon followed by the cloning of a novel G-protein 
coupled receptor that displayed very high homology with 
Figure 4. 3D model for the MOP receptor.
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opioid receptors but did not bind opioid ligands (Mollereau 
et al. 1994; Meunier et al. 2000). This receptor was then 
deorphanized by discovering its endogenous ligand the hep-
tadecapeptide nociceptin/orphanin FQ (N/OFQ) (Meunier et 
al. 1995; Reinscheid et al. 1995). This was the first successful 
example of the reverse pharmacology approach (Civelli et al. 
1998). The N/OFQ and its N/OFQ peptide receptor (NOP re-
ceptor), (Cox et al. 2000) are widely distributed in the central 
nervous system, but also in the periphery and in the immune 
system (Mollereau and Mouledous 2000). Accordingly, N/
OFQ elicits a broad range of biological effects such as modu-
lation of pain transmission, of anxiety and response to stress, 
learning and memory, food intake, locomotor activity. Gene 
structure and chromosomal localization have also described 
both for the N/OFQ peptide and the NOP receptor, moreover 
knock-out animals lacking the neuropeptide gene have been 
generated and studied (Mollereau et al. 1996; Nothacker et 
al. 1996; Reinscheid et al. 2000).
The activity of known genes can be modified in vivo us-
ing gene-targeting technology. Mice lacking opioid peptides 
or opioid receptors have been generated by homologous 
recombination (Kieffer 1999). MOP receptor deficient mice 
have been generated by disrupting exon 1 (Sora et al. 1997), 
exon 2 (Matthes et al. 1996) or exons 2 and 3 (Loh et al. 
1998). All morphine responses investigated so far are nulli-
fied in MOP receptor knock-out (KO) mice: analgesia after 
acute s.c. administration in tail immersion-1 (Matthes et al. 
1996), tail-flick- (Sora et al. 1997) and hotplate tests (Sora 
et al. 1997); analgesia after intrathecal or i.c.v. administra-
tion, respiratory depression (Matthes et al. 1998); constipa-
tion (Roy et al. 1998); acute morphine treatment induced 
modification of locomotor activity (Tian et al. 1997); euphoria 
(Matthes et al. 1996); chronic morphine treatment induced 
physical dependence, withdrawal symptoms (Matthes et al. 
1996); chronic morphine treatment induced immunosupres-
sion (Gaverieaux-Ruff et al. 1998). The generation of mice 
deficient in DOP receptors was reported by Zhu et al. (1999), 
and Filliol et a1. (2000). Homologous recombination led to 
exon 1- or exon 2 deleted mice. Simonin et al. reported mice 
lacking KOP receptors (Simonin et al. 1998). Targeting was 
directed to delete the first coding exon. Mice lacking all 
three opioid receptor genes have been obtained in a two-step 
strategy. Breeding of mice lacking MOP receptor exon 2 
(Matthes et al. 1996) with mice lacking KOP receptor exon 1 
(Simonin et al. 1998) produced MOP-/KOP- double mutants, 
while breeding of the former with exon 1 DOP deficient mice 
(Filliol et al. 2000) produced MOP-/DOP- double mutants. 
Triple mutants were obtained from MOP-/KOP- x MOP-/DOP- 
matings. These animals showed no [3H]DAMGO, [3H]CI-977 
and [3H]DPDPE binding sites, as expected from the parental 
phenotypes (Simonin et al. 2001). The analysis of responses 
of MOP, DOP and KOP receptor-deficient mice to prototypic 
opiates has clarified the role of each opioid receptor in the 
main actions of opiate drugs. The MOP receptors are essential 
for the activity of morphine and trigger the large set of well-
known opiate activities that are clinically useful or relevant to 
opiate addiction. The KOP receptors mediate both dysphoric 
and analgesic activities of classical KOP agonists. DOP 
receptors produce analgesia, do not mediate opioid reward 
and dependence and may have other roles, such as improving 
mood states. Finally, MOP and DOP receptors may interact 
functionally while KOP receptors act independently.
Very recently the high resolution (2.8 Å) crystal structures 
of all four opioid receptors have been resolved (Manglik et 
al. 2012; Wu et al. 2012; Thompson et al. 2012; Granier et 
al. 2012). Compared to the buried binding pocket observed 
in most G-protein-coupled receptors published so far, the 
morphinan ligand binds deeply within a large solvent-exposed 
pocket. Of particular interest, the MOP receptor crystallizes 
as a two-fold symmetrical dimer through a four-helix bundle 
motif formed by TM segments 5 and 6 (Manglik et al. 2012). 
The crystal structure of the human KOP receptor in complex 
with the selective antagonist JDTic, arranged in parallel 
dimers, at 2.9 Å resolution. The structure reveals important 
features of the ligand-binding pocket that contribute to the 
high affinity and subtype selectivity of JDTic for the human 
KOP receptor. Modelling of other important KOP receptor-
selective ligands, including the morphinan-derived antago-
nists norbinaltorphimine and 5′-guanidinonaltrindole, and 
the diterpene agonist salvinorin A analogue RB-64, reveals 
both common and distinct features for binding these diverse 
chemotypes (Wu et al. 2012). The X-ray structure of the NOP 
receptor also shows substantial conformational differences 
in the pocket regions between NOP and the classical opioid 
receptors NOP and KOP receptors and these are probably due 
to a small number of residues that vary between these recep-
tors. The NOP–compound-24 structure explains the divergent 
selectivity profile of NOP and provides a new structural tem-
plate for the design of NOP ligands (Thompson et al. 2012). 
The crystal structure of the mouse DOP receptor complexed 
with naltrindole reveals that the binding pocket of opioid 
receptors can be divided into two distinct regions. Whereas 
the lower part of this pocket is highly conserved among opi-
oid receptors, the upper part contains divergent residues that 
confer subtype selectivity. This provides a structural explana-
tion and validation for the ‘message–address’ model of opioid 
receptor pharmacology, in which distinct ‘message’ (efficacy) 
and ‘address’ (selectivity) determinants are contained within 
a single ligand. Comparison of the address region of the DOP 
receptor with other GPCRs reveals that this structural organi-
zation may be a more general phenomenon, extending to other 
GPCR families as well (Granier et al. 2012). The four opioid 
receptor structures reveal several evolutionarily conserved 
ligand–receptor interactions in the receptors’ binding pockets, 
which are contained within the seven transmembrane helices 
(designated TM1–7) of the receptors. For instance, several 
24
Benyhe et al.
amino-acid residues at the same positions in TM3, TM6 and 
TM7 form interactions with the chemical moieties of ligands 
that are responsible for opioid efficacy - the ‘message’ region 
of the ligands. By contrast, the chemical moieties responsible 
for opioid selectivity - the ‘address’ region - occupy one of 
two different areas of the binding pocket, depending on the 
type of opioid. Specifically, the addresses of classical opioids, 
which contain the ‘morphinan’ chemical structure, interact 
with TM6 and/or TM7, whereas the corresponding regions 
of the other opioids studied are positioned between TM2 and 
TM3 of the receptor, forming interactions mostly with those 
helices, but also with TM7 (Filizola and Devi 2012). 
Opioid receptor signaling
Opioid receptors mostly couple to Gαi/o type G-proteins (Bur-
ford et al. 2000), thus when activated they decrease intracel-
lular cAMP levels by inhibiting adenylate cyclase activity 
(Johnson et al. 1994), decrease calcium ion entry (Bourinet 
et al. 1996) and increase potassium ion efflux (Ivanina et al. 
2004), which in turn inhibit the presynaptic release of differ-
ent types of neurotransmitters such as GABA, noradrenaline, 
acetylcholine or dopamine (Mansour et al. 1995). Due to 
these signaling pathways opioid receptors regulate several 
important physiological and pathological functions, such as 
analgesia, euphoria, physical dependence, gastrointestinal 
motility (Koneru et al. 2009), psychiatric disorders (Lutz et al. 
2013), memory and learning (Bodnar 2013), respiration and 
thermoregulation, eating, drinking and many other functions 
(for review see Bodnar 2013).
In recent years there has been an emerging concept in 
GPCR signaling, including opioid receptors, called ligand-
directed signaling or biased signaling. According to this 
concept GPCR receptors can exist in multiple structural stages 
and different agonist stabilize the receptors in selective struc-
tural phases, resulting in distinct signaling pathways (Kenakin 
2011; Reiter et al. 2012). Recently it has been shown that 
GPCRs can mediate G-protein independent signaling through 
proteins such as β-arrestins, which can act as scaffolding 
molecules, through which several signaling cascades can be 
initiated (Rajagopal and Zastrow 2009; Sorkin et al. 2010). 
Biased agonism has been described in all three classical opi-
oid receptors and has been reviewed recently (Pradhan et al. 
2012). Opioid receptor biased agonist have been proven to be 
potential therapeutic drugs, for instance µ biased agonists are 
better analgesics with reduced abused liabilities, while δ and 
κ biased agonists are promising candidates for the treatment 
of pain and mood disorders (Pradhan et al. 2012).
Opioid receptor dimerization
The idea of GPCR dimerization goes back to the 1980s 
(Birdsall 1982), however even afterwards the most accepted 
model was, which proposed that a single GPCR interacts 
with a single G-protein (González-Maeso 2011). GPCR di-
merization gain much more attention after the development 
of chimeric muscarinic M3/α
2C 
adrenergic receptors (Maggio 
et al. 1993), which demonstrated the first indirect evidence 
for GPCR dimerization (González-Maeso 2011). Also the 
evidence that GPCR heteromerization can alter ligand bind-
ing and receptor signaling (Jordan and Devi 2000; Bowery 
and Enna 2000) led to the widely acceptance of the GPCR 
hetero-and homomer concept.
Among the opioid receptors, firstly δ- and κ-opioid recep-
tors were found to form heteromers (Jordan and Devi 2000). 
The δ-κ heteromer showed distinct ligand binding and func-
tional properties from either receptor and synergistically binds 
highly selective agonists and enhances signaling (Jordan and 
Devi 2000). According to Grupta and co-workers, chronic 
morphine treatment induced µ-δ heteromer formation in brain 
regions which are important in drug addiction (Grupta et al. 
2010). There is also evidence for dimerization between opioid 
and non-opioid receptors, for instance µ-opioid and α
2a 
adren-
ergic receptors can directly communicate with each other 
through the receptor complex (Jordan et al. 2003; Vilardaga 
et al. 2008). Opioid and cannabinoid receptor type 1 (CB
1
) 
heteromers have also a great literature: µ-CB
1 
(Hojo et al. 
2008) and δ-CB
1
 (Rozenfeld et al. 2012) receptor heteromers 
were described by FRET and BRET studies.
endogenous opioid peptides as natural 
ligands for opioid receptors
Endogenous opioid peptides in general
Natural ligands for multiple opioid receptors are endogenous 
opioid peptides. Opioid peptides are short sequences of amino 
acids that specifically bind to opioid receptors in the brain; 
opiates and opioids mimic the effect of these peptides. Opioid 
peptides may be produced by the body itself, for example 
endorphins. The effects of these peptides vary, but they all 
resemble those of opiates. Brain opioid peptide systems are 
known to play an important role in motivation, emotion, at-
tachment behaviour, the response to stress and pain, and the 
control of food intake. Two related pentapeptides, Leu- and 
Met-enkephalin (Hughes et al. 1975) were the first endog-
enous opioid peptides identified in different mammalian spe-
cies including the human. Enkephalins have relatively high 
affinities for DOP receptors, two- to fivefold lower affinities 
for MOP receptors and substantially smaller affinity for KOP 
receptors. The discovery of enkephalins was soon followed 
by the discovery of β-endorphin (Li and Chung 1976). Later 
a potent opioid peptide with KOP receptor selectivity and 
very high affinity was described and named dynorphin 1-17 
(Goldstein et al. 1979, 1981).
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Endogenous opioid peptides are derived from three 
precursors referred to as proopiomelanocortin (POMC), 
proenkephalin (PENK) and prodynorphin (PDYN) (Nakani-
shi et al. 1979; Noda et al. 1982; Kakidani et al. 1982). Each 
polypeptide precursor is subjected to sequential enzymatic 
cleavages, transport and other posttranslational modifications 
resulting in multiple bioactive peptides. These endogenous 
opioids share the common N-terminal sequence of Tyr-Gly-
Gly-Phe-Met/Leu (YGGFM/L), which has been termed either 
“enkephalin motif” or “message sequence” (Schwyzer, 1986); 
this pattern can be followed by various C-terminal extensions 
yielding other mature peptides ranging from 6 to 31 residues 
in length. Classical opioid peptides starting with tyrosine 
moiety (Tyr1) are specifically interacting with the MOP, DOP 
and KOP receptors. According to phylogenetic analyses the 
PENK gene is considered to be the primordial opioid pro-
peptide gene (Dores et al. 1993). This is the ‘proenkephalin 
hypothesis’. Gene duplication is a recurring theme in the evo-
lution of vertebrate polypeptide hormones and neuropeptides. 
It has been proposed that during the evolution of the opioid 
peptides at least two duplication events occurred in the most 
ancestral PENK gene (Dores et al. 1993). Consistent with 
the proenkephalin hypothesis, the first gene duplication event 
would have produced the POMC gene, which is the common 
precursor for the non-opioid adrenocorticotrop hormone 
(ACTH) and the three melanocyte stimulating hormones (α, 
β, γ MSHs) and the opioid untriacontapeptide β-endorphin. A 
further duplication event would have given rise to the PDYN 
gene. The proenkephalin hypothesis and the evolution of the 
opioid peptide precursor genes have been described in more 
details (Khalap et al. 2005; Roberts et al. 2007; Komorowski 
et al. 2012). Another scenario for gene duplications has been 
proposed more recently. Opioid peptide gene family members 
were investigated using a combination of sequence-based 
phylogeny and chromosomal locations of the peptide genes 
in various Vertebrates (Sundström et al. 2010). The results 
showed that the ancestral PENK gene gave rise to two additi-
onal copies in the genome doublings. The fourth member was 
generated by a local gene duplication, as the genes encoding 
POMC and PNOC are located on the same chromosome in 
several teleost and bird genomes that have been studied. In 
conclusion, the system of opioid peptides and receptors was 
largely formed by the genome doublings that took place early 
in vertebrate evolution.
Enkephalins
Among multiple opioid peptides the enkephalins have the wi-
dest tissue distribution. The structural organization of PENK 
includes an N-terminal signal peptide sequence followed by 
a cysteine rich domain and then the coding region for the 
mature oligopeptides interrupted by short non-processing 
segments. Mammalian PENK contains seven copies of 
enkephalins bordered by basic dipeptide repeats, such as 
Arg-Arg, Lys-Lys or Lys-Arg (RR, KK, KR). These dibasic 
residues represent recognition sites for the processing endo-
peptidase enzymes, called prohormone convertases (Hook 
et al. 2008). Upon cleavage terminal basic amino acids are 
typically removed. Seven opioid core motifs exists within 
PENK and Met-enkephalin units are present as repetitive 
sequences with a copy number of six, while one single copy 
of Leu-enkephalin is also present at the sixth core position. 
Beside the pentapeptides, two extended Met-enkephalin 
sequence forms exist: the fourth opioid motif is the octapep-
tide Met-enkephalin-Arg-Gly-Leu (MERGL) and the PENK 
C-terminal is indeed a heptapeptide with the structure of 
Met-enkephalin-Arg-Phe (MERF).
Nociceptin/orphanin FQ
The neuropeptide nociceptin/orphanin FQ (N/OFQ) was si-
multaneously identified as endogenous ligand for an orphan 
opioid-like receptor (Mollereau et al. 1994) by pioneer appli-
cations of the reverse pharmacology approach (Meunier et al. 
1995; Reinscheid et al. 1995). N/OFQ is a heptadecapeptide 
(FGGFTGAR KSARKLANQ) sharing some sequence simi-
larities with the endogenous kappa-opioid receptor (KOPr) 
agonist peptide dynorphin A. Likewise, the highest primary 
sequence identity/homology of the NOP receptor are obser-
ved with the KOPr. A unique and distinguishing difference 
between opioid peptides and N/OFQ is that the N-terminal 
message motif is YGGF in the opioids (Schwyzer 1986), 
while the corresponding N-terminal tetrapeptide segment in 
N/OFQ is composed of FGGF. This difference may be suf-
ficient to prevent N/OFQ binding to opioid receptors. The 
address domain of N/OFQ is relatively long and involves 
centrally located positively charged amino acids (Tancredi 
et al. 2005).
Endomorphins
Endomorphins are a group of lately discovered endogenous 
opioid peptides consisting of endomorphin-1 (Tyr-Pro-
Trp-Phe-NH
2
) and endomorphin-2 (Tyr-Pro-Phe-Phe-NH
2
) 
(Zadina et al. 1997). They are C-terminally amidated tetra-
peptides with the highest known affinity and specificity for 
the µ-opioid receptor. Endomorphin-1 is found in the nucleus 
of the solitary tract, the periventricular hypothalamus, and the 
dorsomedial hypothalamus, where it is found within histamin-
ergic neurons and may regulate sedative and arousal behaviors 
(Greco et al. 2008). It is assumed that endomorphins are the 
cleavage products of a larger precursor, but this polypeptide 
or protein has not yet been identified. 
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Modelling of opioid receptors
Introduction
Modelling the receptors or receptor-ligand interactions in-
volves a wide range of the computational methods such as 
quantum chemical (QM), molecular dynamics (MD) and its 
variants, multivariate statistics (chemometrics) which is the 
mathematical toolkit for the quantitative structure-activity 
relationships studies (QSAR), homology modelling (which 
uses knowledge based statistical potentials) and molecular 
docking algorithms.
Ligand based modelling
Although the ligand based structure-activity studies are 
performed to compare the ligands and to make predictions 
for new drugs without the knowledge anything about the 
receptor, simultenuously they result in assumptions on the 
complementer receptor structure. Numerous structure-activity 
studies have been made in the opioid field (e.g., Subrama-
nian and Ferguson 2000; Wong et al. 2002; Piestrzeniewicz 
et al. 2006; Fürst and Hosztafi 2008; Janecka et al. 2010; 
Mustazza and Bastanzio 2011). These studies provided 
quite accurate spatial pharmacophore necessities for both 
agonists, antagonists on the ligand side (e.g., Feinberg et al. 
1976; Loew et al. 1978; Loew and Burt 1978; Misicka 1995; 
Fournie-Zaluski et al. 1981; Schiller et al. 1983; Brandt et 
al. 1993; Subramanian and Ferguson 2000). Furthermore, 
despite the missing protein structure, a great advance was 
made in the receptor theory. The initial approximation of 
the enzyme-ligand interactions, the “lock-and-key” theorem 
(Fischer 1894) implied a rigid protein structure based on the 
high ligand specificity of the enzymes. Later, recognizing 
the variations in the pharmacophore arrangement of ligands 
with very similar activity profile, the “induced fit” theory 
was introduced assuming flexibility of the binding site of the 
receptor too (Koshland 1958). Studying the selectivity profiles 
on a vast number of peptide and non-peptide ligands, another 
feature of the ligand-receptor interactions was discovered and 
named as “message-address” concept (Portoghese et al. 1987; 
Portoghese et al. 1988) arising from the opioid research as 
seen above. Obviously, to fulfill the immediate need for quan-
titative estimation and prediction of the effect of the ligands, 
efficient QSAR methods have been developed. Among many, 
the 3D-QSAR methods proved to be especially powerful 
contributing to the development of new drugs as well (e.g., 
McGovern et al. 2010). Because flexibility has always been a 
crucial problem in the interaction models, 4D- and 5D-QSAR 
methods emerged to involve the flexibility of the ligand and 
the receptor (Duca and Hopfinger 2001; Vedani and Dobler 
2002). Alternative methods to address the ligand flexibility 
were also developed (Loew and Burt 1978; Chew et al. 1993; 
Martinek et al. 2005; Dervarics et al. 2006). QSAR methods 
are also suitable for large scale screening of compound librar-
ies which is a common task nowadays.
Receptor based modelling
Modelling the structure of opioid (or any other) receptors 
is aimed by two mutually fruitful reasons: on one hand, 
the knowledge of the structure and function of the receptor 
makes possible the rational (i.e. structure or receptor based) 
drug design and, in the other hand, the ligands with known 
effects can help to reveal how the receptor functions. In 
either case, the molecular interactions between the ligands 
and the receptor are to be explored, because the response of 
the receptor upon ligand binding specifically depends on the 
ligand-receptor complex. The resulting response classifies the 
ligands by their nature such as agonists, antagonists, inverse 
agonists or partial agonists and ranks them by binding affinity 
as well. The bottleneck in the receptor modelling is always 
to obtain the protein structure. The most valuable way is to 
start with an experimental structure but, due to the decent 
number of solved X-ray structures of membrane proteins 
(now including the opioid receptors), most protein model-
ling should start with theoretically derived structure, mostly 
by homology modelling (Vyas et al. 2012). However, good 
homology models are based on experimental structures of 
evolutionally related proteins which were not available in 
the early times of the opioid research. Due to the fact that 
the orthosteric binding site of the opioid receptors is among 
the membrane spanning helices it was possible to construct 
limited receptor models missing the extra- and intracellular 
loops as well as the N- and the C-terminal tails. These models 
utilized the quantified lipid- and polar facing propensities of 
the constituting amino acids obtained by multiple sequence 
alignment comparison of the already sequenced GPCRs and 
were able to explain the receptor ligand interactions including 
the selectivity profiles (Donnelly et al. 1993). It is important 
to note that the contact regions between the transmembrane 
helices determined by this method are the same than those 
obtained by a completely different, statistical-phylogenetic 
analysis of the GPCR family (Süel et al. 2003). Bera et al. 
(2011) investigated the quality of the homology models of 
MOR, DOR and KOR depending on the templates used in 
modelling. Having the protein structure in hand there are 
two different modelling methods to continue with, namely 
docking and molecular dynamics, both of them are based on 
molecular force fields.
Molecular docking with opioid receptors
Docking algorithms are designed for fast calculation of op-
timized ligand-receptor complexes and so forth are widely 
used for high throughput screening of compound libraries. 
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They apply simplified molecular force fields with entropic 
and solvation corrections resulting in score functions to rank 
the interacting poses of the ligand bound to the receptor 
(reviewed by e.g., Meng et al. 2011). The usual way is to 
keep the protein either rigid or flexible while the ligand is 
flexible with rotatable dihedral angles in its structure. As an 
exception applied in docking program FRED, the flexibility 
of the ligands is simulated by pregenerated conformer set 
of the ligand which than are docked rigidly to the receptor 
(McGann 2011). Using single rigid receptor conformation 
corresponds to the “lock-and-key” approximation. Most dock-
ing programs have built in algorithms to mimic the flexibility 
of the receptor, corresponding to the “induced fit” theory, by 
rotating the side chains of selected residues while keeping 
the protein backbone rigid. However, the choice of flexible 
side chains is important and it greatly influences the result of 
docking calculations (Abreu et al. 2012). The limited receptor 
flexibility involving only the side chains is overcomed by the 
program DOCK which allows finishing the docking procedure 
with a molecular dynamics phase using implicit water model 
for solvation (Moustakas 2006) that now allows the move-
ment of any atom of the protein. Another approach to sample 
the protein flexibility is to generate conformer ensembles by 
molecular dynamics and using them rigidly in the docking 
(Nakajima et al. 1997).
It is also important which conformational state of the 
receptor is used for the docking calculations (Cui et al. 
2013). As an example, screening a database against the 
crystal structure of β2-adrenergic receptor complexed with 
an inverse agonist, the hits were also inverse agonists; one 
of them with high binding affinity (Kolb et al. 2009). As a 
comparison, docking a database to the crystal structure of 
the KOR complexed with an antagonist found an agonist, 
although the affinity was rather weak (Negri et al. 2013). The 
κ selectivity was enforced by sorting out those compounds 
that showed interactions characteristic to MOR and DOR 
selective ligands. 
Sagara et al. (1996) identifed the ligand-binding residues 
of MOR by docking dihydromorphine derivatives to the active 
receptor modell. Fentanyl derivatives were shown to adopt 
similar conformations in solution and docked to MOR modell 
(Huang et al. 2000). It was found that fentanyl and its analogs 
interact with the crucial Asp3.32 but other interactions with 
the receptor are different than those of morphinan opiates 
(Subramanian et al. 2000; Dosen-Micovic et al. 2006). The 
different selectivity profiles of the MOR and DOR receptors 
were modelled by docking cyclic enkephalin analogues, 
JOM6 and JOM13, to the homology modelled structures and 
proved by mutagenesis studies (Mosberg and Fowler 2002). 
It was earlier reported that the constrained peptide JOM13 
can bind the DOR with good docking energy, however in a 
somewhat different manner, than the well known opioid al-
kaloids (Mosberg 1999). It was also shwon that investigating 
the ligands alone was not able to select the dockable confor-
mation, whithout the docking calculations. Opioid ligands 
lacking the classical ammonium ion present a new group. A 
cyclic endomorphin 1 analogue was shown to bind to MOR 
differently than JOM6, a high affinity and selectivity µ opioid 
ligand but it could still activate the mu receptor (Gentilucci et 
al. 2008). Lesma and co-workers (2013, 2013a) synthesized 
and investigated endomorphin analogues with beta-amino 
acid replacements and found that despite the higher steric 
requirements they could adopt very similar docked positions 
than the parent compound.
Micovic and co-workers (2009) showed, by docking a 
series of morphinan derivatives to different rigid DOR con-
formations, that the ligands prefer different receptor states 





 specificity. Using accurate receptor models, partially 
based on the crystal structures, an efficient µ agonist/delta 
antagonist cyclized peptidomimetic ligand with mixed phar-
macological profile was designed (Anand et al. 2012). This 
emphasizes the value of the rational drug design based on a 
good receptor model.
The interacting residues of KOR, responsible for selec-
tivity and efficacy of a series of arylacetamide-based opioid 
agonists, were discovered by docking calculations (Subra-
manian et al. 1998). It was also shown that the only common 
feature in the binding mode with the traditional morphinan 
derivatives was the ionic interaction of the ligand with 
Asp138 in TM3, i.e. the conserved opiate interaction with 
D3.32. Cappelli et al. (1996) reported a quantitative model 
for molecular docking based structure-activity relationship 
for KOR selective benzodiazepine derivatives. The structural 
determinants responsible for binding were deduced from the 
docking calculations. Docking arylacetamide and benzomor-
phan derivative agonists to KOR showed the conserved salt 
bridge with D3.32 and both hydrogen bonding and hydro-
phobic interactions with Y7.35 and H6.52 (Lavecchia et al. 
2000). A combined ligand- and receptor-based method was 
developed for Salvinorin A analogues resulting in a quantita-
tive pharmacophor model (Singh et al. 2006). and by docking 
assisted with molecular dynamics.
Huang et al. (2000a) investigated the binding modes 
of nociceptin, etorphine and four lofentanyl stereomers to 
nociceptin receptor model. They found a good correlation 
between the experimental binding constants and docking en-
ergies. For the potent and NOP selective agonist Ro 64-6198 
and analogues, a common hydrophobic cavity was identified 
in the homology modelled receptor (Bröer et al. 2003). The 
pharmacophore arrangement was determined by 3D-QSAR 
modelling first, then the ligands were docked to the receptor 
preserving the conserved D3.32 ionic interaction. A similar 
scenario was perfomed on spiropiperidine analogues to find 
the binding interactions (Liu et al. 2010).
The message-address concept was directly addressed in an 
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early study comparing the selectivity features of naltrexone, 
naltrindole and norbinaltorphimine by docking these ligands 
to opioid receptor homology models (Metzger et al. 1996); 
recently a more exhaustive investigation applied a higher 
number of the ligands and the crystal structures of the recep-
tors (Zaidi et al. 2013). The interacting residues identified by 
the docking and structure-activity studies are compared with 
the recent crystal structures (Filizola and Devi 2012) and 
shown for MOP receptor in Figure. 5.
Molecular dynamics with opioid receptors
Molecular dynamics (MD) simulation is able to discover 
the molecular interactions at atomic level as a series of time 
events. Its current accuracy can be demonstrated by a com-
puter simulation of an antagonist binding spontaneously to the 
receptor reproducing the experimental crystal structure (Dror 
et al. 2011b), although at an extremely high cost of computer 
time. However, a huge amount of structural information has 
been collected about the opioid receptors by more limited 
MD methods.
The investigation of the pharmacophores of the peptides 
and other highly flexible ligands can only be performed by 
MD methods and by comparison with other ligands. Over-
lapping structural elements of enkephalin and naltrindole, 
i.e. the Phe4 side chain and the benzene moiety of the fused 
indol, respectively, were found to be responsible for selectiv-
ity (Portoghese et al. 1991). A bent backbone was obtained 
for [Met5]- and [D-Ala2,Met5]-enkephalins and an identical 
pharmacophore arrangement with that of morphine (Ishida 
et al. 1988). The energy minimized conformers of the same 
peptides were also compared to find the most overlaping 
conformers that are most probably the bioactive conformers 
(Loew and Burt 1978). These conformers were overlaping 
with the pharmacophores of a rigid opiate ligand. Interest-
ingly, these conformers were not the lowest energy ones and 
shared a bent backbone too. For endomorphin 2 and its ana-
logues was also found that the bent backbone is predominant 
for the more potent analogues (Borics et al. 2012). Numer-
ous other MD studies were performed on peptide ligands to 
find the active conformation for dermorphins (Mierke et al. 
1990; Wilkes and Schiller 1992), deltorphins (Segawa et al. 
1994), enkephalins (Chew et al. 1993; Mishra et al. 1994; 
Bryant et al. 1994; Gussmann et al. 1996; Shenderovich et 
al. 2000; Shen My and Freed 2002), endomorphins (Podlogar 
et al. 1998; Borics and Tóth 2010), and dynorphins (Collins 
and Hruby 1994). Bernard and co-workers (2003, 2005) 
developed a MD based method to distinguish agonists and 
antagonists.
Molecular dynamics simulations of the receptors reveal 
the understanding of their functioning. In early studies only 
the transmembrane helix bundle was built by homology mod-
eling and subjected to MD simulation. Comparative studies 
involving all three opioid receptors resulted in stable struc-
tures preserving all helix contacts characteristic to the GPCRs 
but showed differences capable of explaining the selectivities 
(Strahs and Weinstein 1997; Filizola et al. 1999). With a simi-
larly built model of KOR refined by MD in a phospholipid and 
water environment, different binding regions were found for 
the endogenous dynorphin and for synthetic ligands (Iadanza 
et al. 2002). A more complete DOR model involving the loop 
regions too was built and refined by MD however, it was not 
able to explain the sodium effect and ligand binding inter-
actions (Aburi and Smith 2004). A model of MOR refined 
by MD in lipid and water reproduced the binding mode of 
naltrexone by docking (Zhang et al. 2005).
A non-opioid type binding mode to KOR was modelled 
for Salvinorin A, a non-classical opioid ligand, to explain its 
selectivity (Vortherms et al. 2007). The involvement of EL2 
and rotation of TM2 was assumed resulting in a rearrange-
ment of the binding pocket.
The importance of the conserved disulfide bridge between 
C3.25 and EL2 was investigated by mutagenesis studies for 
MOR (Zhang et al. 1999) and DOR (Ehrlich et al. 1998). In 
both cases the receptors lost the specificity and high affinity 
for high affinity opioid ligands. This is presumably due to 
the change in the overall conformation of the receptors af-
fecting the ligand binding region too. The activation of the 
membrane embedded KOR was modelled by simulated an-
nealing method and concluded that only the agonist disrupted 
the ionic lock (Kolinski and Filipek 2010). Similarly, the 
activation of MOR was modelled in the presence of morphine 
(Serohijos et al. 2011). The activation of nociceptin receptor 
involved movements of transmembrane helices 3 and 6 (Daga 
and Zaveri 2012). For DOR Collu and co-workers (2012) 
Figure 5. Binding pocket and receptor surfaces of the MOP receptor.
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simulated the movement of agonists. The allosteric effect 
of sodium ion (“sodium-effect”) was modelled by long MD 
study in the case of MOR (Yuan et al. 2014) and for all three 
opioid receptor types (Shang et al. 2014).
The binding mode of endomorphin analogues in the active 
MOR was modelled by MD starting with docked structures 
(Liu et al. 2009). The resulting models conformed well with 
the statements of the message-address concept and the results 
obtained by mutagenesis studies. Liu and co-workers (2009a) 
modelled the mu-delta receptor dimerization by all-atom 
MD concluding that the transmembrane helices 1, 7 of the 
mu receptor and 4, 5 of the delta receptor are facing in the 
stabil model.
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